Introduction: The analysis was conducted to assess a cost-efficacy analysis of new antiemetic drugs (netupitant plus palonosetron (NEPA)) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly and moderately emetogenic chemotherapy for cancer treatment. Areas covered:The present evaluation was restricted to pivotal phase III randomized controlled trials (RCTs) of NEPA versus (vs.) palonosetron for the prophylaxis of CINV. We calculated the pharmacological costs necessary to get the benefit in complete response (CR), for each trial. Our analysis evaluated 2 RCTs, including 1720 patients. Referring to both highly and moderately emetogenic chemotherapy, NEPA plus DEX was economic superior to palonosetron (PALO) plus DEX, with 13 312 € and 7885 € gain in medical costs every 100 patients treated, respectively. The cost-effectiveness ratios (CERs) (€/CR) in highly emetoge nic risk were 1.24 and 13.23 for the NEPA and PALO group, respectively and 1.49 and 15.20 for the same groups in moderately emetogenic risk. The incremental cost-effectiveness ratio (ICER) between the groups was 1016.18 €/CR and 1024.03 €/CR in highly and moderately emetogenic risk, respectively. Expert opinion:The combination of NEPA plus DEX is cost-effective for preventing CINV in highly and moderately (AC-based) emetogenic cancer treatment.

中文翻译：

---

Netupitant加上帕洛诺司琼是一种经济有效的治疗方法，可用于预防由化疗引起的恶心和呕吐，适用于高度和中度致癌的癌症治疗。

简介：进行该分析是为了评估新的止吐药（netupitant加帕洛诺司琼（NEPA））在高和中度致呕性化疗中预防化疗引起的恶心和呕吐（CINV）的成本效益分析。涵盖的领域：本评估仅限于NEPA相对于帕洛诺司琼（相对于帕洛诺司琼）预防CINV的关键性III期随机对照试验（RCT）。对于每个试验，我们计算了获得完全缓解（CR）益处所需的药理费用。我们的分析评估了2项RCT，包括1720例患者。对于高和中度致癌化疗，NEPA加DEX在经济上优于帕洛诺司琼（PALO）加DEX，每治疗100例患者，其医疗费用分别增加13 312€和7885€。NEPA和PALO组在高呕吐风险中的成本-效果比（€/ CR）分别为1.24和13.23，中度致呕吐风险的同一组分别为1.49和15.20。两组之间，在高和中度致呕风险中的增量成本效益比（ICER）分别为1016.18€/ CR和1024.03€/ CR。专家意见：NEPA与DEX的结合在高和中度（基于AC的）致癌性癌症治疗中预防CINV具有成本效益。